These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 1676393)

  • 1. [Supersensitive detection of tyrosine hydroxylase mRNA and neuroblastoma cells by reverse transcription and polymerase chain reaction].
    Naito H
    Hokkaido Igaku Zasshi; 1991 Mar; 66(2):135-41. PubMed ID: 1676393
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Detection of tyrosine hydroxylase mRNA and minimal neuroblastoma cells by the reverse transcription-polymerase chain reaction.
    Naito H; Kuzumaki N; Uchino J; Kobayashi R; Shikano T; Ishikawa Y; Matsumoto S
    Eur J Cancer; 1991; 27(6):762-5. PubMed ID: 1676900
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-time RT-PCR of tyrosine hydroxylase to detect bone marrow involvement in advanced neuroblastoma.
    Pession A; Libri V; Sartini R; Conforti R; Magrini E; Bernardi L; Fronza R; Olivotto E; Prete A; Tonelli R; Paolucci G
    Oncol Rep; 2003; 10(2):357-62. PubMed ID: 12579272
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-time analysis of tyrosine hydroxylase gene expression: a sensitive and semiquantitative marker for minimal residual disease detection of neuroblastoma.
    Lambooy LH; Gidding CE; van den Heuvel LP; Hulsbergen-van de Kaa CA; Ligtenberg M; Bökkerink JP; De Abreu RA
    Clin Cancer Res; 2003 Feb; 9(2):812-9. PubMed ID: 12576454
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcome prediction by molecular detection of minimal residual disease in bone marrow for advanced neuroblastoma.
    Horibe K; Fukuda M; Miyajima Y; Matsumoto K; Kondo M; Inaba J; Miyashita Y
    Med Pediatr Oncol; 2001 Jan; 36(1):203-4. PubMed ID: 11464885
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection of neuroblastoma cells in bone marrow and peripheral blood at diagnosis by the reverse transcriptase-polymerase chain reaction for tyrosine hydroxylase mRNA.
    Miyajima Y; Kato K; Numata S; Kudo K; Horibe K
    Cancer; 1995 Jun; 75(11):2757-61. PubMed ID: 7743482
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection of micrometastasis of neuroblastoma to bone marrow and tumor dissemination to hematopoietic autografts using flow cytometry and reverse transcriptase-polymerase chain reaction.
    Tsang KS; Li CK; Tsoi WC; Leung Y; Shing MM; Chik KW; Lee V; Ng MH; Yuen P
    Cancer; 2003 Jun; 97(11):2887-97. PubMed ID: 12767104
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic impact of the detection of microcirculating tumor cells by a real-time RT-PCR assay of tyrosine hydroxylase in patients with advanced neuroblastoma.
    Parareda A; Gallego S; Roma J; Llort A; Sábado C; Gros L; De Toledo JS
    Oncol Rep; 2005 Oct; 14(4):1021-7. PubMed ID: 16142367
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of neuroblastoma cells during clinical follow up: advanced flow cytometry and rt-PCR for tyrosine hydroxylase using both conventional and real-time PCR.
    Esser R; Glienke W; Bochennek K; Erben S; Quaiser A; Pieper C; Eggert A; Schramm A; Astrahantseff K; Hansmann ML; Schwabe D; Klingebiel T; Koehl U
    Klin Padiatr; 2011 Nov; 223(6):326-31. PubMed ID: 22095188
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of two methods for evaluating bone marrow metastasis of neuroblastoma: Reverse transcription-polymerase chain reaction for tyrosine hydroxylase and magnetic resonance imaging.
    Takemoto C; Nishiuchi R; Endo C; Oda M; Seino Y
    Pediatr Int; 2004 Aug; 46(4):387-93. PubMed ID: 15310300
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neuroblastoma initially presenting as a primary bone tumor: diagnostic value of molecular assays for tyrosine hydroxylase.
    Robles-Frías MJ; Segura DI; Márquez C; Quiroga E; Alvarez AM; Sáez C
    Med Pediatr Oncol; 2003 Mar; 40(3):167-70. PubMed ID: 12518346
    [No Abstract]   [Full Text] [Related]  

  • 12. Comparison of immunocytochemistry, real-time quantitative RT-PCR and flow cytometry for detection of minimal residual disease in neuroblastoma.
    Ifversen MR; Kågedal B; Christensen LD; Rechnitzer C; Petersen BL; Heilmann C
    Int J Oncol; 2005 Jul; 27(1):121-9. PubMed ID: 15942651
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PHOX2B is a novel and specific marker for minimal residual disease testing in neuroblastoma.
    Stutterheim J; Gerritsen A; Zappeij-Kannegieter L; Kleijn I; Dee R; Hooft L; van Noesel MM; Bierings M; Berthold F; Versteeg R; Caron HN; van der Schoot CE; Tytgat GA
    J Clin Oncol; 2008 Nov; 26(33):5443-9. PubMed ID: 18838715
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disease outcome may be predicted by molecular detection of minimal residual disease in bone marrow in advanced neuroblastoma: a pilot study.
    Fukuda M; Miyajima Y; Miyashita Y; Horibe K
    J Pediatr Hematol Oncol; 2001 Jan; 23(1):10-3. PubMed ID: 11196262
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Minimal residual disease at the time of peripheral blood stem cell harvest in patients with advanced neuroblastoma.
    Burchill SA; Kinsey SE; Picton S; Roberts P; Pinkerton CR; Selby P; Lewis IJ
    Med Pediatr Oncol; 2001 Jan; 36(1):213-9. PubMed ID: 11464888
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection of microscopic disease: comparing histology, immunocytology, and RT-PCR of tyrosine hydroxylase, GAGE, and MAGE.
    Cheung IY; Cheung NK
    Med Pediatr Oncol; 2001 Jan; 36(1):210-2. PubMed ID: 11464887
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Measurement of tyrosine hydroxylase transcripts in bone marrow using biopsied tissue instead of aspirates for neuroblastoma.
    Lee ST; Suh YL; Ko YH; Ki CS; Sung KW; Kim HJ; Kim JW; Kim SH; Chueh H; Lee SH; Yoo KH; Koo HH
    Pediatr Blood Cancer; 2010 Aug; 55(2):273-8. PubMed ID: 20582938
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantitative analysis of tyrosine hydroxylase mRNA for sensitive detection of neuroblastoma cells in blood and bone marrow.
    Träger C; Kogner P; Lindskog M; Ponthan F; Kullman A; Kågedal B
    Clin Chem; 2003 Jan; 49(1):104-12. PubMed ID: 12507966
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detection of microscopic neuroblastoma in marrow by histology, immunocytology, and reverse transcription-PCR of multiple molecular markers.
    Cheung IY; Barber D; Cheung NK
    Clin Cancer Res; 1998 Nov; 4(11):2801-5. PubMed ID: 9829745
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantitation of GD2 synthase mRNA by real-time reverse transcription-polymerase chain reaction: utility in bone marrow purging of neuroblastoma by anti-GD2 antibody 3F8.
    Cheung IY; Lo Piccolo MS; Collins N; Kushner BH; Cheung NK
    Cancer; 2002 Jun; 94(11):3042-8. PubMed ID: 12115395
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.